| Bioactivity | IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (Kd=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease[1]. HBx: hepatitis B virus X protein. | ||||||||||||
| Target | Kd: 2 nM (IR415-HBx interaction) | ||||||||||||
| Invitro | Hepatitis B virus X protein (HBx) as a suppressor of host defenses consisting of RNAi-based silencing of viral genes[1].IR415 (50-200 μM) has a dose-dependent inhibitory effect on HBx, with a minimal effective concentration of 50 μM in HepG2/GFP-shRNA line transfected with HBx[1]. | ||||||||||||
| Name | IR415 | ||||||||||||
| CAS | 452967-14-5 | ||||||||||||
| Formula | C13H14F2N4S | ||||||||||||
| Molar Mass | 296.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ghosh S, et al. An RNAi-based high-throughput screening assay to identify small molecule inhibitors of hepatitis B virus replication.J Biol Chem. 2017 Jul 28;292(30):12577-12588. |